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we found no signiﬁcant difference in rates of the composite end point
between patients receiving PCI and those undergoing CABG at 1 year
follow-up.
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BACKGROUND Longitudinal geographic miss (LGM) is associated with
higher incidences of post-PCI adverse outcomes. Robotic-assisted PCI
(R-PCI) has been shown to be safe and feasible. The incidence of LGM in
R-PCI compared to standard manual PCI (M-PCI) was analyzed.
METHODS Patients evaluated underwent R-PCI (CorPath 200 System,
Corindus Vascular Robotics, Inc., Waltham, MA) in the PRECISE study
andM-PCI in the STLLR trial. A core laboratory evaluated target lesions
for LGM and graded according to ACC/AHA criteria as simple (A and B1)
or complex (B2 and C). LGM was deﬁned as the entire length of the
injured or stenotic segment not being fully covered by the total length
of the stent. To be Included in the analysis at least one stent had to be
placed during the indexprocedure and adetermination of LGMcould be
made. The overall, and by simple and complex lesion group assignment
incidence of LGMwas compared between the R-PCI andM-PCI cohorts.
RESULTS A total of 164 R-PCI patients and 1509 M-PCI patients met the
criteria for inclusion. Baseline characteristics are detailed in Table 1.
Overall, the R-PCI cohort exhibited a statistically lower incidence of LGM
when compared to M-PCI, 12.2% to 43.1% (p<0.0001). The R-PCI patients
had a signiﬁcantly lower incidence of LGM, in both the simple lesion (7.3%
vs 28.7%, P<0.001) and complex lesion (15.4% vs 48.0%, P<0.001).Table 1. Patient, Lesion, and Procedure CharacteristicsPatient Characteristics RA-PCI (n[164) M-PCI (n[1509) P ValueAge (years) 64.1  10.0 63.6  11.3 0.4825
Men 122 (74.4%) 1005 (66.6%) 0.0440Previous MI 83 (50.6%) 311 (20.6%) 0.0022History of PCI 129 (78.7%) 484 (32.0%) <0.0001History of CABG 10 (6.1%) 167 (11.1%) <0.0001Unstable Angina 94 (57.3%) 459 (30.4%) <0.0001Stable Angina 47 (28.7%) 708 (46.9%) 0.1051Diabetes Mellitus 58 (35.4%) 427 (28.3%) 0.0253Hypertension 141 (86%) 1150 (76.1%) 0.0016Dyslipidemia 145 (88.4%) 1145 (75.8%) <0.0001Lesion/Procedure CharacteristicsTarget Vessel Location <0.0001Left Main 0 (0%) 13 (0.9%)LAD 53 (32.3%) 632 (41.9%)LCX 43 (26.2%) 360 (23.9%)RCA 62 (37.8%) 504 (33.4%)ACC/AHA Lesion Classiﬁcation <0.0001A 47 (28.7%) 21 (1.4%)B1 65 (39.6%) 345 (22.9%)Total A/B1 (Simple Lesions) 112 (68.3%) 366 (24.3%)B2 31 (18.9%) 888 (58.8%)C 21 (12.8%) 236 (15.6%)Total B2/C (Complex Lesions) 52 (31.7%) 1124 (74.5%)Unclassiﬁed 0 (0%) 19 (1.3%)Pre-ProcedureLesion length (mm) 13.4  4.0 14.8  9.2 0.0007
Lesion diameter stenosis (%) 78.1  10.0 61.7  12.5 <0.0001
Lesion minimal lumen diamter (%) 0.95  0.33 1.00  0.39 0.1717
Lesion reference diameter (mm) 3.04  0.40 2.61  0.53 <0.0001Post-ProcedureLesion diameter stenosis (%) 4.9  7.9 16.7  10.8 <0.0001
Lesion minimal lumen diameter (%) 2.59  0.43 2.28  0.50 <0.0001
Lesion reference diameter (mm) 2.73  0.46 2.73  0.45 0.9654No. of Stents Per Patient 0.17541 152 (92.7%) 1383 (91.7%)2 9 (5.5%) 116 (7.7%)3 3 (1.8%) 8 (0.5%)4 0 (0%) 2 (0.1%)LGM Overall 20/164 (12.2%) 650/1509 (43.1%) <0.0001LGM Simple Lesions 12/112 (10.7%) 105/366 (28.7%) 0.0002LGM Complex Lesions 8/52 (15.4%) 539/1124 (48.0%) <0.0001LGM Unclassiﬁed - 6/19 (31.6%)CONCLUSIONS Robotic-assisted PCI had signiﬁcantly lower incidence
of LGM compared to standard manual PCI. These results suggest that
R-PCI may reduce the incidence of LGM. Further studies are needed to
conﬁrm the results and elucidate their impact on outcomes.
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BACKGROUND Durable polymer-based drug-eluting stents have been
reported to adversely affect the safety proﬁle and are also suspected to
B198 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5cause serious long-term complications. It has been proposed that the
biodegradable polymer coatings may reduce such late-stage adverse
effects. The purpose of this registry was to evaluate clinical outcomes
of an ultra-thin (60mm) biodegradable polymer-coated sirolimus-
eluting Supraﬂex (Sahajanand Medical Technologies Pvt. Ltd., Surat,
India) stent for the treatment of coronary artery disease across a wide
range of unselected patients treated in routine clinical practice,
including those with high-risk characteristics and complex lesions.
METHODS The FLEX-Registry was a retrospective, multicenter, all-
comers, observational registry of patients implanted with the Supra-
ﬂex sirolimus-eluting stent (SES). A total of 995 patients with 1,184
lesions were analyzed from 9 different tertiary care centers in India
between July-2013 to May-2014. Patients were included if their index
procedures were completed using only the Supraﬂex SES. The primary
endpoint was 9-month major adverse cardiac events (MACE, deﬁned
as the composite of cardiac death, myocardial infarction [MI], target
lesion revascularization [TLR], and target vessel revascularization
[TVR]). We also evaluated stent thrombosis rate through 9-month; as
deﬁned by the Academic Research Consortium (ARC) criteria.
RESULTS The FLEX-Registry evaluated high risk patients, including
441 (44.3%) hypertensive patients, 231 (23.2%) diabetic patients, 775
(65.5%) type B2/C lesions, and 185 (15.6%) totally occluded lesions.
The average number of stents per patient was 1.410.56; and mean
stent length was 26.69.3 mm. Clinical follow-up at 9-month was
completed in 99.1% of patients (986/995). MACE rates at in-hospital,
30-day and 6-month were 0.4% (4/995), 1.1% (11/995) and 2.2% (22/
986). At 9-month, the primary endpoint occurred in 26 (2.6%) of 986
patients, consisting of 11 (1.1%) cardiac deaths, 16 (1.6%) MI, and 6
(0.6%) TLR. Cumulative MACE-free survival at the 9-month clinical
follow-up determined by Kaplan-Meier method was 97.4%. According
to the ARC deﬁnition, deﬁnite and probable stent thrombosis occurred
in 1.1% (11/986) of patients until the 9-month follow up.
CONCLUSIONS The FLEX-Registry evaluated clinical outcomes in
real-world and more complex cohorts and thereby provides evidence
to the clinicians for safe and routine extended use of Supraﬂex SES to
a broader percutaneous coronary intervention population.
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BACKGROUND The impact of operator experience and volume of left
main (LM) percutaneous coronary intervention (PCI) performed yearly
on outcomes after LM PCI is unknown. To characterize the impact of
LM-PCI operator’s experience and volume on the occurrence of
adverse events after LM-PCI.
METHODS High volume LM-PCI operators were deﬁned as performing
at least 15 LM PCI cases per year, for at least 3 consecutive years.
Thirty day and 3-year outcomes were reported and compared between
high-volume and low-volume operators.
RESULTS From January 2004 to December 2011, 25 operators per-
formed 1,948 LM-PCI in a single center. Among them, 7 were
considered high-volume and performed 1,422 (73%) LM-PCI and 18
operators were considered low-volume and performed 526 (27%)
procedures. The mean number of LM-PCI performed each year per
operator was 258 and 43 in the high-volume and low-volume
group, respectively. Patients treated within the high-volume operator
group were in general more complex, with higher SYNTAX score,
higher SYNTAX score II, more often 3-vessel disease, and with more
frequently LM lesions involving the distal segment (bifurcation)
requiring two stents implantation. Intravascular ultrasound was more
often used by the high-volume operators compared to the other group
(39.2% vs. 31.7%). Thirty-day outcomes demonstrated signiﬁcantly
lower rates of death and cardiac death, with trend toward lower rateof myocardial infarction and stent thrombosis (Figure). At 3 years of
follow-up, patients treated with high-volume operators showed
signiﬁcantly lower rate of cardiac death (2.5% vs. 4.6%, p¼0.02), with
no signiﬁcant difference in rate of ischemia driven target vessel
revascularization (6.8% vs. 5.1%. p¼0.20) when compared with the
low-volume operators. After multivariate analysis, high-volume LM
operator group was associated with freedom of 3-year cardiac death
(adjusted HR 1.90 95% CI ¼ [1.10, 3.30] p ¼ 0.02).
CONCLUSIONS Despite treating more complex and higher-risk patients,
high-volume operators had better short and long-term prognostic
compared with low-volume operators when performing LM-PCI. These
ﬁndings could be important when consideringminimal operator’s volume
requirement for the treatment of this high-risk lesion subset.
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BACKGROUND Women with coronary artery disease (CAD) undergo-
ing percutaneous coronary intervention (PCI) are at higher risk of
early and late major adverse cardiac events (MACE) compared with
male subjects. Moreover, previous studies suggest a differential
prognostic impact of clinical presentation between genders. In this
study, we sought to investigate the effect of gender according to
clinical presentation on clinical outcomes.
METHODS We retrospectively analyzed patients from a large single-
center PCI registry treated between January 2009 and December 2013.
Study population was categorized according to gender and presence
or not of myocardial infarction (MI) at time of PCI. Endpoints of in-
terest were all-cause mortality, MI and cerebrovascular events (CVEs)
at 1 year after the index procedure.
RESULTS Out of 15,988 patients included in the present analysis,
10,764 (67%) were males and 5224 (33%) were females. Of them, 1,198
(7%) and 672 (4%) presented with an MI in the male and female group,
respectively. In both groups, women were older, more commonly
affected by multiple comorbidities but had lower CAD complexity
compared with men. A stepwise increase in the rates of mortality, MI
and CVE was observed in the transition from male with no MI, to fe-
male with no MI, to male with MI to female with MI (Figure 1).
Following multivariable adjustment for baseline confounders, women
with MI had similar risk of all-cause mortality (HR: 1.02; 95% CI: 0.81 –
1.28), MI (HR: 1.55; 95% CI: 0.93 – 2.59) and CVE (HR: 2.44; 95% CI:
0.64 – 9.36) to that of the male counterpart. The effect of gender
across clinical presentation was uniform, without evidence for inter-
action for the investigated outcomes.
